Iclepertin(BI-425809) is a potent and selective inhibitor of glycine transporter 1 (GlyT1) that increases glycine levels in the cerebrospinal fluid (CSF).

DCZ0415 is a potent inhibitor of TRIP13. DCZ0415 impairs nonhomologous end joining repair and inhibits NF-κB activity. It triggers anti-myeloma effects both in vitro, and in vivo, and primary cells obtained from myeloma patients resistant to drugs.

Iclepertin(BI-425809) is a potent and selective inhibitor of glycine transporter 1 (GlyT1) that increases glycine levels in the cerebrospinal fluid (CSF).

Iclepertin(BI-425809) is a potent and selective inhibitor of glycine transporter 1 (GlyT1) that increases glycine levels in the cerebrospinal fluid (CSF).

Iclepertin(BI-425809) is a potent and selective inhibitor of glycine transporter 1 (GlyT1) that increases glycine levels in the cerebrospinal fluid (CSF).

PI3K/AKT-IN-1 is a dual-acting inhibitor of PI3K/AKT pathway with an IC50 of 6.99 µM, 4.01 µM, and 3.36 µM, for PI3Kδ, PI3Kγ and AKT-1 respectively. It also induces S-phase cell cycle arrest, caspase-3-dependent apoptosis, exhibiting strong potential against breast cancer and leukemia.

PI3K/AKT-IN-1 is a dual-acting inhibitor of PI3K/AKT pathway with an IC50 of 6.99 µM, 4.01 µM, and 3.36 µM, for PI3Kδ, PI3Kγ and AKT-1 respectively. It also induces S-phase cell cycle arrest, caspase-3-dependent apoptosis, exhibiting strong potential against breast cancer and leukemia.

PI3K/AKT-IN-1 is a dual-acting inhibitor of PI3K/AKT pathway with an IC50 of 6.99 µM, 4.01 µM, and 3.36 µM, for PI3Kδ, PI3Kγ and AKT-1 respectively. It also induces S-phase cell cycle arrest, caspase-3-dependent apoptosis, exhibiting strong potential against breast cancer and leukemia.

PI3K/AKT-IN-1 is a dual-acting inhibitor of PI3K/AKT pathway with an IC50 of 6.99 µM, 4.01 µM, and 3.36 µM, for PI3Kδ, PI3Kγ and AKT-1 respectively. It also induces S-phase cell cycle arrest, caspase-3-dependent apoptosis, exhibiting strong potential against breast cancer and leukemia.

Claturafenib (PF-07799933) is a brain-penetrant, selective, pan-mutant inhibitor of BRAF. It exhibits broad inhibition of pERK levels in HT29 cells with an IC50 value of 1.6 nM. PF-07799933 treatment displays antitumor activity against BRAFV600- and non-V600-mutant cancers preclinically and in treatment-refractory patients.